SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
June 29, 2004
NASTECH PHARMACEUTICAL COMPANY INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE
(STATE OR OTHER JURISDICTION OF INCORPORATION)
| | | |
| 000-13789 | | 11-2658569 |
| (COMMISSION FILE NUMBER) | | (I.R.S. EMPLOYER IDENTIFICATION NO.) |
| | | |
| 3450 Monte Villa Parkway | | |
| Bothell, Washington | | 98021 |
| (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) | | (ZIP CODE) |
(425) 908-3600
(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
TABLE OF CONTENTS
ITEM 5. OTHER EVENTS.
On June 29, 2004, Nastech Pharmaceutical Company Inc. (the “Registrant”) issued a press release in which it reported Phase 1-C clinical results of PYY3-36 Nasal Spray for Obesity.
A copy of the press release issued by the Registrant concerning the foregoing results is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
The following exhibit is filed herewith.
Exhibit 99.1 — Press Release dated June 29, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | NASTECH PHARMACEUTICAL COMPANY INC.
(Registrant)
| |
| | By: | /s/ Gregory L. Weaver | |
| | | Name: | Gregory L. Weaver | |
| | | Title: | Chief Financial Officer | |
| |
Dated: June 29, 2004
